Primary Immune Tribune   Primary Immune Tribune
  E-newsletter of the Immune Deficiency Foundation

April 2009 VOLUME 4 ISSUE 4  

Contents
Action Alert! - We Need Your Help!
IDF 2009 National Conference
Jenny Gardner Video
My IVIG brand was changed!
Since You Asked
IDF Calendar of Events
Subscribe
Submit your info to
receive future editions
via e-mail:

Type of Member

Health Professional
 Patient
Patient's parent/guard.
 Relative of patient
 Friend of patient
 Volunteer
 General Inquiry

Email Address:

First Name:

Last Name:

Address Line 1:

Address Line 2:

City:

State:

Country:

Postal Code:

Phone Number:


Archive
SPECIAL CONFERENCE EDITION
March 20, 2009
March 2009
March 2, 2009
Vol. 4 Issue 3
February 2009
February 1, 2009
Vol. 4 Issue 2

[MORE]

Action Alert! - We Need Your Help!
New Senate Legislation to fix Access and Reimbursement

New Senate legislation was introduced March 25, 2009 to fix access and reimbursement for IVIG in the 111th Congress. Senators John Kerry (MA), Lamar Alexander (TN), Sheldon Whitehouse (RI), Ron Wyden (OR) and Sam Brownback (KS), introduced the Senate Bill S. 701, The Medicare Patient IVIG Access Act.


[FULL STORY]
 

IDF 2009 National Conference
REGISTER NOW!

Register today and join us to "Celebrate Our Community" at the IDF 2009 National Conference, the largest gathering of our extraordinary IDF community, June 18–20, 2009, at Disney’s Contemporary Resort in Florida.


[FULL STORY]
 

Jenny Gardner Video
Watch Jenny's Video on Being Denied Treatment

Jenny Gardner is an IDF patient and volunteer from West Palm Beach, Florida.  Jenny’s life and livelihood were threatened when she was unfairly denied access to her IVIG.  Click here to hear Jenny’s story.


 

My IVIG brand was changed!
What do I need to know?

The reasons a patient may be switched from one IVIG product to another include clinical factors, fiscal issues, and/or product availability.  Regardless of the underlying reason for the change, there are several factors involved with IVIG treatment, which should be considered such as the rate of infusion, the concentration, the product itself, as well as the patient’s health status at the time of infusion.  All these factors can influence how you will tolerate the infusion of a new IVIG product.


[FULL STORY]
 

Since You Asked
IDF Question and Answer

Q:  My doctor no longer participates with my insurance company.  When I made my appointment, he was still a participating provider, but he just cancelled his contract with them last month.  I had no knowledge of this until I received a huge bill in the mail today from my doctor – Help!

 

Q:  I heard that there are new COBRA premium rules in the Stimulus package – Can you tell me what these changes mean?

Click on "Full Story" to learn the answers to these questions.


[FULL STORY]
 

IDF Calendar of Events
[FULL STORY]
 

Primary Immune Tribune is sponsored by an educational grant from Talecris Biotherapeutics


Powered by IMN